| Cardiovascular Health and Disease Prevention | Lifetime | 11 | SE 1 | 99.87 |
| Blood Pressure and Hypertension Studies | Lifetime | 26 | SE 1 | 99.83 |
| Heart Rate Variability and Autonomic Control | Lifetime | 45 | SE 1 | 99.70 |
| GDF15 and Related Biomarkers | Lifetime | 6 | SE 2 | 99.25 |
| Effects and risks of endocrine disrupting chemicals | Lifetime | 52 | SE 2 | 99.51 |
| Parathyroid Disorders and Treatments | Lifetime | 67 | SE 3 | 99.32 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 167 | SE 2 | 99.45 |
| Cardiovascular Function and Risk Factors | Lifetime | 236 | SE 4 | 99.53 |
| Cardiovascular Disease and Adiposity | Lifetime | 117 | SE 4 | 99.32 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 178 | SE 3 | 99.29 |
| Diet and metabolism studies | Lifetime | 452 | SE 12 | 99.15 |
| Vitamin D Research Studies | Lifetime | 116 | SE 2 | 98.83 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 212 | SE 12 | 98.93 |
| Health, Environment, Cognitive Aging | Lifetime | 93 | SE 5 | 98.30 |
| Toxic Organic Pollutants Impact | Lifetime | 272 | SE 18 | 98.77 |
| Cardiovascular and exercise physiology | Lifetime | 351 | SE 14 | 98.41 |
| Per- and polyfluoroalkyl substances research | Lifetime | 76 | SE 6 | 98.21 |
| Metabolomics and Mass Spectrometry Studies | Lifetime | 594 | SE 17 | 97.20 |
| Diet, Metabolism, and Disease | Lifetime | 516 | SE 16 | 97.54 |
| Heart Failure Treatment and Management | Lifetime | 568 | SE 21 | 97.95 |
| Genetic Associations and Epidemiology | Lifetime | 405 | SE 8 | 97.87 |
| Nutrition and Health in Aging | Lifetime | 766 | SE 26 | 97.46 |
| Emergency and Acute Care Studies | Lifetime | 600 | SE 6 | 97.04 |
| Diabetes Treatment and Management | Lifetime | 801 | SE 27 | 97.26 |
| Nitric Oxide and Endothelin Effects | Lifetime | 802 | SE 15 | 97.13 |
| Metabolism, Diabetes, and Cancer | Lifetime | 914 | SE 30 | 97.00 |
| Hormonal Regulation and Hypertension | Lifetime | 929 | SE 28 | 96.59 |
| Nutrition, Genetics, and Disease | Lifetime | 422 | SE 8 | 95.32 |
| Lipoproteins and Cardiovascular Health | Lifetime | 930 | SE 21 | 96.57 |
| Magnesium in Health and Disease | Lifetime | 153 | SE 4 | 95.69 |
| Renal function and acid-base balance | Lifetime | 444 | SE 10 | 95.78 |
| Non-Invasive Vital Sign Monitoring | Lifetime | 859 | SE 9 | 94.02 |
| Genetic Syndromes and Imprinting | Lifetime | 771 | SE 23 | 93.10 |
| Biomarkers in Disease Mechanisms | Lifetime | 311 | SE 6 | 90.40 |
| Sodium Intake and Health | Lifetime | 557 | SE 9 | 92.42 |
| Macrophage Migration Inhibitory Factor | Lifetime | 671 | SE 14 | 84.40 |
| Heart rate and cardiovascular health | Lifetime | 943 | SE 28 | 62.03 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 56 | SE 1 | 97.70 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 41 | SE 3 | 97.79 |
| Diet and metabolism studies | 2021-2025 | 213 | SE 5 | 97.48 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 119 | SE 2 | 96.45 |
| Genetic Associations and Epidemiology | 2021-2025 | 180 | SE 3 | 95.96 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 290 | SE 6 | 95.40 |
| GDF15 and Related Biomarkers | 2021-2025 | 58 | SE 4 | 87.25 |
| Cerebrovascular and Carotid Artery Diseases | 2021-2025 | 907 | SE 14 | 91.27 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 490 | SE 7 | 87.64 |
| Per- and polyfluoroalkyl substances research | 2021-2025 | 367 | SE 15 | 86.90 |
| Fatty Acid Research and Health | 2021-2025 | 425 | SE 9 | 80.82 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 905 | SE 13 | 54.27 |
